It is often said that “disease knows no borders,” but is the same true for clinical development? Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case, with longstanding biases towards studies in the US and Europe, where health care infrastructure and the pharmaceutical market are generally more mature. However, change is underway.
APAC As A Clinical Trial Powerhouse
In the last 10 years, APAC has become a hotspot for clinical trials: the region contributed almost 50% of new clinical trial activity globally in 2021.
